ONP-002
Concussion / mild Traumatic Brain Injury (mTBI)
Phase 2Phase 1 complete; preparing Phase 2 launch
Key Facts
Indication
Concussion / mild Traumatic Brain Injury (mTBI)
Phase
Phase 2
Status
Phase 1 complete; preparing Phase 2 launch
Company
About Oragenics
Oragenics is striving to revolutionize neurological care through its proprietary intranasal delivery technology, which bypasses the blood-brain barrier to enable targeted, non-invasive brain therapeutics. The company's lead program, ONP-002, has completed Phase 1 safety studies for concussion and is preparing for Phase 2, with a broader pipeline including ONP-001 for rare leukodystrophies and a vaccine program. Oragenics is a public company (NYSE American: OGEN) positioning itself at the intersection of neurology and innovative drug delivery.
View full company profile